Waters (WAT) Stock
Global lab instrument maker for drug development and testing. Here's the price, business snapshot, and what's worth knowing about Waters in July 2026.
Waters Corporation (WAT) designs and manufactures laboratory analytical instruments — notably high-performance liquid chromatography and mass spectrometry systems — used to separate, identify and quantify chemical compounds. Its products, consumables and services serve pharmaceutical, biotech, chemical, food-safety and environmental laboratories worldwide. Revenue typically comprises capital equipment sales and recurring aftermarket consumables and service contracts, which can provide resilient cash flow but remain sensitive to capital spending cycles. Waters benefits from a strong installed base, long product lifecycles and regulatory-driven demand in drug development and quality control. Key considerations for investors include exposure to global pharmaceutical investment, competition from other instrument makers, currency and supply-chain risks, and the ongoing need for R&D. Market cap: $20.79B. This is general information for education, not personalised advice; values can rise or fall and past performance is not a guide.
Why It’s Moving
Waters Corp Shares Surge on Analyst Buoyancy as 2026 Forecast Points to 32% Upside Amid Strong Sector Momentum
- : Analysts have issued a consensus 'Buy' rating, citing a 2026 average price target that forecasts a 32% increase, signaling strong confidence in the company's ability to capitalize on rising global demand for precision testing equipment.
- : Earnings projections for 2027 show net income per share climbing to $16.55, with implications that the company is successfully navigating operational complexities while maintaining a competitive edge in the analytical instrumentation market.
- : The sector-wide trend of increased capital investment in biotech research is fueling positive sentiment, with analysts noting that Waters Corp's diversified product portfolio is well-aligned to capture this accelerating market expansion.
Waters Corp Shares Surge on Analyst Buoyancy as 2026 Forecast Points to 32% Upside Amid Strong Sector Momentum
- : Analysts have issued a consensus 'Buy' rating, citing a 2026 average price target that forecasts a 32% increase, signaling strong confidence in the company's ability to capitalize on rising global demand for precision testing equipment.
- : Earnings projections for 2027 show net income per share climbing to $16.55, with implications that the company is successfully navigating operational complexities while maintaining a competitive edge in the analytical instrumentation market.
- : The sector-wide trend of increased capital investment in biotech research is fueling positive sentiment, with analysts noting that Waters Corp's diversified product portfolio is well-aligned to capture this accelerating market expansion.
When is the next earnings date for WATERS CORP (WAT)?
The next earnings report for Waters Corporation (WAT) is estimated to be released on August 3, 2026, though the company has not yet officially confirmed this date. This announcement will cover the company's second-quarter (Q2) fiscal 2026 results. Based on historical reporting schedules, the Q2 earnings date typically falls in early August, aligning with the current estimate. Investors should monitor official company filings for the final confirmed release date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Waters Corporation's stock with a target price of $372.85, indicating growth potential.
Financial Health
Waters Corporation is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring WAT
Navigating the Forever Chemicals Crackdown Explained
Following the Texas Attorney General's investigation into Lululemon over "forever chemicals," the apparel industry is bracing for a massive regulatory shift toward non-toxic materials. This creates a compelling investment opportunity in specialized testing laboratories, compliance auditors, and sustainable apparel brands poised to capitalize on the global PFAS phase-out.
Published: 14 April 2026
Explore BasketPersonal Care Safety: Could Talc Verdict Boost Stocks?
A record $1.5 billion verdict against Johnson & Johnson in a talc cancer case highlights the immense legal and financial risks associated with certain consumer product ingredients. This creates a compelling investment opportunity in companies that provide safer, alternative materials and advanced testing services for the personal care industry.
Published: 24 December 2025
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketLife Sciences Brazil | Clinical Trial Stock Exposure
Brazil's expanding role in global medical research may increase local access to cutting-edge treatments and stimulate economic growth. This basket provides exposure to the theme through US and EU-listed companies that supply critical services and infrastructure for clinical trials in the region.
Published: 3 November 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: 23 July 2025
Explore BasketBeyond The Ozarks: Trusted Outdoor Brands
This carefully selected group of stocks represents established outdoor and drinkware brands poised for growth. Our professional analysts have identified these companies as potential beneficiaries of shifting consumer preferences toward trusted, premium products following Walmart's major safety recall.
Published: 11 July 2025
Explore BasketPure Water Plays: Investing in Trusted Alternatives
Following investigations into Nestlé's water filtration practices, consumers may seek more transparent water options. These carefully selected stocks represent companies that could benefit from this shift, from beverage competitors to water purification technology providers.
Published: 11 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Aftermarket Revenue Strength
Consumables and service contracts create steady recurring income that can stabilise revenue, though instrument orders remain cyclical and can vary.
Pharma & Regulation Demand
Demand from drug development and regulatory testing supports long-term need for high-end instruments, but exposure to regulatory cycles and geographic shifts adds variability.
Innovation & Competition
Continued R&D keeps the product line competitive in high-precision analytics, yet heavy R&D spend and rival technologies present execution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
